The chronic myeloproliferative disorders: clonality and clinical heterogeneity.
The chronic myeloproliferative disorders (MPD), polycythemia vera (PV), chronic idiopathic myelofibrosis (IMF), essential thrombocytosis (ET), and chronic myelogenous leukemia (CML), are thought to be clonal disorders arising in a multipotent hematopoietic progenitor cell. However, establishing the diagnosis of an MPD other than CML is problematic due to a lack of clinically applicable clonal markers. Furthermore, in some patients, in whom a classical MPD phenotype is present, the hematopoietic stem cells appear to be polyclonal, suggesting that the chronic MPD other than CML may actually be a genetically heterogeneous group of disorders. Furthermore, since the aberrant clone is believed to arise from a multipotent hematopoietic stem cell, the non-CML chronic MPD-ET, PV, and IMF-could be related. Additional unresolved issues regarding the MPD include: identification of the multipotent hematopoietic progenitor cell involved, the molecular basis for the clinical heterogeneity amongst the individual MPD, the clinical significance of clonality in non-CML MPD, and reconciliation of therapy with the clonal and clinical heterogeneity of these disorders. Determination of clonality has largely been carried out using X chromosome-linked polymorphisms, but such studies are limited to women and with increasing patient age are compromised by skewing of allelic expression in both neutrophils and T lymphocytes, making the results difficult to interpret. X chromosome-linked polymorphism studies have indicated that in PV the target stem cell is one that gives rise to both lymphoid and myeloid progenitors. Recently, two epigenetic markers have been identified in the MPD: impaired expression of the thrombopoietin receptor, Mpl, in platelets and megakaryocytes, and overexpression in neutrophils of the mRNA of a gene designated polycythemia rubra vera-1 (PRV-1). The role of these epigenetic abnormalities in the diagnosis of the MPD remains to be established. Currently, given the unresolved issues with respect to the clinical and clonal heterogeneity of the MPD, treatment needs to be tailored individually in patients with an MPD.
Spivak
Jerry L
JL
Hematology Division, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
D000367:Age Factors; D000483:Alleles; D014408:Biomarkers, Tumor / Q000235:genetics*; D001792:Blood Platelets / Q000473:pathology; D002454:Cell Differentiation / Q000235:genetics; D041321:Chromosomes, Human, X; D005260:Female; D058851:GPI-Linked Proteins; D018740:Genetic Heterogeneity; D006412:Hematopoietic Stem Cells / Q000473:pathology*; D006801:Humans; D007519:Isoantigens / Q000235:genetics; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000235:genetics / Q000473:pathology / Q000628:therapy; D008533:Megakaryocytes / Q000473:pathology; D008562:Membrane Glycoproteins / Q000235:genetics; D009196:Myeloproliferative Disorders / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D009363:Neoplasm Proteins / Q000235:genetics; D009504:Neutrophils / Q000473:pathology; D011110:Polymorphism, Genetic / Q000235:genetics; D011518:Proto-Oncogene Proteins / Q000235:genetics; D012333:RNA, Messenger; D011956:Receptors, Cell Surface; D018121:Receptors, Cytokine / Q000235:genetics; D053628:Receptors, Thrombopoietin; D013601:T-Lymphocytes / Q000473:pathology
D014408:Biomarkers, Tumor; C407242:CD177 protein, human; D058851:GPI-Linked Proteins; D007519:Isoantigens; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger; D011956:Receptors, Cell Surface; D018121:Receptors, Cytokine; D053628:Receptors, Thrombopoietin; C082218:MPL protein, human